Skip to content
Brand AI

Eisai

Controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile3 entries

  1. 2023

    Ransomware attack and logistics disruption

    Eisai experienced a ransomware attack in June 2023 that caused the shutdown or disruption of some logistical systems. The incident was a cybersecurity and business-continuity event affecting company operations.

    Source

  2. 2021

    Eisai and Arena Pharmaceuticals sued over Belviq

    Lawsuit filed

    In 2021, a plaintiff and his deceased wife sued Eisai and Arena Pharmaceuticals in the District of New Jersey, alleging that the companies knew or should have known that Belviq could pose a cancer risk. The complaint included product-liability and other claims. The allegations are presented as claims in the lawsuit and are not presented as a court determination.

    Source excerpt

    • Pharmaceutical company Eisai was sued alongside Arena Pharmaceuticals in the District of New Jersey on Monday by a plaintiff and his deceased wife, who alleged that the drug companies knew or should have known that Belviq, a prescription drug designed to be paired with diet and exercise to assist weight loss, could cause a risk of cancer.
    • Specific counts raised against the defendants include product liability, fraud, breach of warranty, violations of New Jersey state consumer protection law, and other claims.
    Source

  3. 2020

    Eisai voluntarily withdraws Belviq

    Recall announced

    Eisai said it agreed to voluntarily withdraw Belviq and Belviq XR from the U.S. market at the FDA’s request after study data showed a higher cancer rate among participants taking Belviq. Eisai said it disagreed with the FDA’s interpretation of the safety data.

    Company response

    • Recall — Eisai

      Japan’s Eisai Inc., said it was voluntarily withdrawing the drug, Belviq.

    Source excerpt

    • An extended-release version of the drug called Belviq XR also is being pulled from the market.
    • The maker of a weight loss drug pulled it from the market Thursday at the request of federal regulators, who said it posed an increased risk of cancer.
    • Japan’s Eisai Inc., said it was voluntarily withdrawing the drug, Belviq.
    Source